Global and China Stem Cell Industry Report, 2014-2017
  • Sep.2014
  • Hard Copy
  • USD $2,400
  • Pages:107
  • Single User License
    (PDF Unprintable)       
  • USD $2,250
  • Code: PQ012
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,500
  • Hard Copy + Single User License
  • USD $2,600

Stem cells are undifferentiated biological cells that can differentiate into specialized cells and can divide (through mitosis) to produce more stem cells. Stem cell therapy can be applied to treatment of cardiovascular diseases, leukemia (a kind of hematological system disease), nervous system diseases, damage or lesion of liver, kidney and other parenchymal organs, etc..

Currently, cord blood bank is the fastest-growing and relatively mature market amid stem cell upstream sectors and even the whole industry chain. In 2005, there were 23 cord blood banks worldwide and in 2013 the figure exceeded 480. Global cord blood stem cell (CBSC) storage companies can be roughly divided into two categories: the ones running in a globalized business model, such as Cryo-Cell International and Esperite (formerly known as Cryo-Save Group), and the others giving priority to regional operation e.g. Zhongyuan Union Stem Cell Bioengineering (VCANBIO), Golden Meditech and LifeCell International. However, the companies mainly engaged in cord blood bank business are currently small in scale, only a few with more than 500,000 clients.

The stem cell technology and product research-oriented midstream sector is in its infancy, mostly concentrated in few countries like Europe, America and South Korea. At present, most companies in the industry chain are basically in the red for years running due to huge R&D costs. Nevertheless, attracted by the tremendous market potential in the area of stem cell therapy and enjoying the great encouragement from government policies (e.g. capital subsidy) and the capital support of significant cooperative partners, very few companies have dropped out.

Up to now, altogether 9 sorts of stem cell products have been approved worldwide, 3 of which are in the category of stem cell drugs developed by S. Korean companies, such as MEDIPOST’s adult stem cell drug CARTISTEM for osteoarthritis treatment and the stem cell product Prochymal (MEDIPOST obtained the product via acquiring the Therapeutics business of Osiris Therapeutics) direct at treating children suffering acute graft-versus-host disease (GVHD).

In the meantime, traditional pharmaceutical giants like Novartis are setting about quickly accessing the field through mergers and acquisitions. On Aug. 19, 2014, Novartis reached an acquisition agreement with Gamida Cell (a corporate dedicated to stem cell technology R&D and its application in stem cell transplantation for leukemia patients), which specified that Novartis spend USD35 million in acquiring 15% equity in the latter and win the option to take over the remaining equity in two years with USD165 million; in Sep. 2013, Novartis also entered a cooperation with Regenerex to jointly develop the hematopoietic stem cell platform FCRx of the latter.

干细胞 英文_副本.jpg

Global and China Stem Cell Industry Report, 2014-2017 highlights the followings:
20120114.gifClassification, application, industry chain definition, etc. of stem cells;
20120114.gifMajor enterprises, policies, upstream/midstream/downstream development and prospects, etc. of global stem cell industry;
20120114.gifPolicies, upstream/midstream/downstream development, etc. of China stem cell industry;
20120114.gifOperation, stem cell business, etc. of 6 upstream companies and 19 midstream/downstream companies worldwide.

1. Overview of Stem Cell Industry
1.1 Definition
1.2 Classification & Application
1.3 Industry Chain
1.4 Development Course

2. Global Stem Cell Industry Chain
2.1 Industry Chain Layout of Major Enterprises
2.2 Policy
2.3 Development
2.4 Upstream
2.5 Downstream
2.6 Prospect

3. China Stem Cell Industry Chain
3.1 Development Introduction
3.2 Policy Environment
3.3 Upstream
3.4 Midstream
3.5 Downstream

4. Upstream Enterprises
4.1 Cryo-Cell International
4.1.1 Profile
4.1.2 Operation
4.1.3 Cord Blood Business
4.2 Esperite
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Stem Cell Business
4.3 Zhongyuan Union Stem Cell Bioengineering
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Stem Cell Business
4.3.7 Development Forecast
4.4 Golden Meditech
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Profit
4.4.5 Cord Blood Business
4.4.6 Development Forecast
4.5 LifeCell International
4.5.1 Profile
4.5.2 Cord Blood Business
4.6 Cryosite
4.6.1 Profile
4.6.2 Operation
4.6.3 Revenue Structure
4.6.4 Stem Cell Business

5. Midstream and Downstream Enterprises
5.1 NeoStem
5.1.1 Profile
5.1.2 Operation
5.1.3 Revenue Structure
5.1.4 R&D
5.1.5 Stem Cell Business
5.2 Mesoblast
5.2.1 Profile
5.2.2 Operation
5.2.3 R&D and Investment
5.2.4 Stem Cell Business
5.3.1 Profile
5.3.2 Operation
5.3.3 Stem Cell Business
5.4 Beike Biotechnology
5.4.1 Profile
5.4.2 Stem Cell Business
5.5 Osiris Therapeutics
5.5.1 Profile
5.5.2 Operation
5.5.3 R&D
5.6 Orthofix International
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 R&D
5.6.5 Stem Cell Business
5.7 Cytori Therapeutics
5.7.1 Profile
5.7.2 Operation
5.7.3 R&D
5.8 Athersys
5.8.1 Profile
5.8.2 Operation
5.8.3 R&D
5.9 Pluristem Therapeutics
5.9.1 Profile
5.9.2 R&D
5.9.3 Recent News
5.10 StemCells
5.10.1 Profile
5.10.2 Operation
5.10.3 R&D
5.11 Advanced Cell Technology
5.11.1 Profile
5.11.2 Operation
5.11.3 R&D
5.12 Celgene
5.12.1 Profile
5.12.2 Operation
5.12.3 R&D
5.13 Vitro Biopharma
5.13.1 Profile
5.13.2 Operation
5.13.3 R&D
5.13.4 Stem Cell Business
5.14 Reneuron
5.14.1 Profile
5.14.2 Operation
5.14.3 R&D
5.15 Tigenix
5.15.1 Profile
5.15.2 Operation
5.15.3 R&D
5.16 Cellular Biomedicine Group, Inc. (CBMG)
5.16.1 Profile
5.16.2 Operation
5.16.3 R&D
5.16.4 Stem Cell Business
5.16.5 Business in China
5.17 Opexa Therapeutics
5.18 ZhongKeBiopharm
5.19 Cyagen Biosciences
Classification of Stem Cell 
Overview of Stem Cell Therapy Area (by Disease Type)
Advantages and Disadvantages of Stem Cell Therapy
Source and Application of Adult Stem Cells (by Type)
Stem Cell Industry Chain
Industry Chain Distribution of Major Global Stem Cell Enterprises
Global Authorized Stem Cell Products and Their Clinical Application
Major Products under Development, Therapeutic Area and Clinical Trial Stage of Global Stem Cell Therapy as of 2014H1
Global Stem Cell Market Size and YoY Growth, 2007-2013
Global Human Stem Cell Clinical Trials and Treatment Application Structure, 2013
Clinical Application of Global Stem Cell Technology (by Disease Type), 2013
Cord Blood Bank Distribution in Major Countries as of 2014H1
Cord Blood Application in Major Countries
Global Top 10 Death Causes (by Death Toll), 2012
Global Top 10 Death Causes (by Income Group), 2012
Global Top 10 Death Causes in Low-income Countries, 2012
Global Top 10 Death Causes in Low- and Middle-income Countries, 2012
Global Top 10 Death Causes in Middle- and High-income Countries, 2012
Global Top 10 Death Causes in High-income Countries, 2012
Global Stem Cell Application Prospect
Global Stem Cell Market Size and YoY Growth, 2014-2017E
Some Chinese Stem Cell Clinical Trial Drugs Approved by CFDA
China Stem Cell Industry Policies, 1999-2014
Major Enterprises and Their Stem Cell Business in China Upstream Stem Cell Industry
Major Enterprises and Their Stem Cell Business in China Midstream Stem Cell Industry 
China Stem Cell Medical Market Size and YoY Growth, 2007-2017E
Revenue, Net Income and Gross Margin of Cryo-Cell International, FY2010-FY2014
Total Assets, Total Liabilities and Asset-liability Ratio of Cryo-Cell International, FY2010-FY2014
Cord Blood Business Revenue and % of Total Revenue of Cryo-Cell International, FY2012-FY2014
Revenue, Net Income and Operating Margin of Esperite, 2009-2014
Revenue Breakdown of Esperite (by Business), 2009-2014
Revenue Structure of Esperite (by Region), 2012VS2013
Stem Cell Storage of Esperite, 2009-2014
Stem Cell Storage Revenue and EBITA of Esperite, 2009-2014
Main Subsidiaries of Zhongyuan Union Stem Cell Bioengineering as of 2014H1
Revenue and Net Income of Zhongyuan Union Stem Cell Bioengineering, 2009-2014
Revenue and Net Income of Zhongyuan Union Stem Cell Bioengineering’s Major Subsidiaries, 2012-2014
Revenue Breakdown of Zhongyuan Union Stem Cell Bioengineering (by Business), 2011-2014
Revenue Breakdown of Zhongyuan Union Stem Cell Bioengineering (by Region), 2010-2014
Gross Margin of Zhongyuan Union Stem Cell Bioengineering (by Business), 2011-2014
R&D Costs and % of Total Revenue of Zhongyuan Union Stem Cell Bioengineering, 2009-2014
Stem Cell Storage Business of Zhongyuan Union Stem Cell Bioengineering (by Type), 2009-2013
Revenue and Net Income of Zhongyuan Union Stem Cell Bioengineering, 2014-2017E
Revenue and Net Income of Golden Meditech, FY2009-FY2013
Revenue Breakdown of Golden Meditech (by Business), FY2009-FY2013
Profit Breakdown of Golden Meditech (by Business), FY2010-FY2013
Cord Blood Bank Revenue and % of Total Revenue of Golden Meditech, FY2011-FY2014
Cord Blood Bank Gross Profit and Gross Margin of Golden Meditech, FY2011-FY2014
Development Course of Golden Meditech’s Cord Blood Storage Business
Revenue and Net Income of Golden Meditech, FY2014-FY2017E
Development Course of LifeCell International
Revenue and Net Income of Cryosite, FY2011-FY2014
Revenue and EBITDA of Cryosite (by Business), FY2011-FY2014
M&A Course of NeoStem, 2009-2014
Revenue and Net Income of NeoStem, 2009-2014
Revenue Breakdown of NeoStem (by Business), 2012-2014
R&D Costs and % of Total Revenue of NeoStem, 2009-2014
Clinical Trial Projects of NeoStem, 2014
Revenue and Net Income of Mesoblast, FY2009-FY2014
R&D Costs and % of Total Revenue of Mesoblast, FY2009-FY2014
M&A Course of Mesoblast by the end of 2013
Stem Cell Product R&D Progress of Mesoblast by the end of June 2014
Revenue, Net Income and Asset-liability Ratio of MEDIPOST, FY2011-FY2013
Adult Stem Cell Drugs and Therapeutic Area of MEDIPOST
Development Course of Beike Biotechnology
Stem Cell Brands and Therapeutic Area of Osiris Therapeutics
Revenue, Net Income and Gross Margin of Osiris Therapeutics, 2011-2014
R&D Costs and % of Total Revenue of Osiris Therapeutics, 2011-2014
Revenue, Net Income and Gross Margin of Orthofix International, 2009-2014
Revenue Breakdown of Orthofix International (by Department), 2011-2014
Revenue Breakdown of Orthofix International (by Region), 2011-2013
R&D Costs and % of Total Revenue of Orthofix International, 2009-2013
Stem Cell Business Revenue of Orthofix International, 2011-2013
Revenue, Net Income and Gross Margin of Cytori Therapeutics, 2009-2014
Revenue Breakdown of Cytori Therapeutics (by Region), 2010-2014
R&D Costs and % of Total Revenue of Cytori Therapeutics, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of Cytori Therapeutics as of 2014H1
Revenue and Net Income of Athersys, 2009-2014
Revenue Breakdown of Athersys (by Source), 2009-2014
R&D Costs and % of Total Revenue of Athersys, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of Athersys as of 2014H1
Significant Cooperative Partners and Areas of Athersys
Stem Cell Products R&D, Therapeutic Area and Progress of Pluristem Therapeutics by the end of Mar. 2014
Revenue, Net Income and Gross Margin of StemCells, 2009-2014
R&D Costs and % of Total Revenue of StemCells, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of StemCells as of 2014H1
Revenue, Net Income and Gross Margin of ACT, 2009-2014
R&D Costs and % of Total Revenue of ACT, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of ACT by the end of 2013
Revenue, Net Income and Operating Margin of Celgene, 2009-2014
Cellular Therapy R&D Costs and % of Total Revenue of Celgene, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Celgene as of 2014H1
Revenue, Net Income and Gross Margin of Vitro Biopharma, FY2009-FY2014
R&D Costs and % of Total Revenue of Vitro Biopharmas, 2011-2014
Stem Cell Brands and Application Fields of Vitro Biopharma
Revenue and Net Income of Celgene, FY2009-FY2013
R&D Costs and % of Total Revenue of Reneuron, 2009-2013
Stem Cell Products R&D, Therapeutic Area and Progress of Reneuron by the end of 2013
Revenue and Net Income of Tigenix, 2009-2014
Sales of Tigenix (by Region), 2011-2013
R&D Costs and % of Total Revenue of Tigenix, 2009-2014
Stem Cell Products R&D, Therapeutic Area and Progress of Tigenix as of 2014H1
Development Course of CBMG
Revenue, Net Income and Operating Margin of CBMG,2009-2014
R&D Costs and % of Total Revenue of CBMG, 2012-2014
Stem Cell Products R&D,Therapeutic Area and Progress of CBMG as of 2014H1

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号